Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.
Ziemssen T, Gilgun-Sherki Y
BMC Neurol. 2015; 15(1):189. Epub 2015 Oct 08. PMID: 26450155.Abstract